Dialysis News and Research RSS Feed - Dialysis News and Research

When your kidneys are healthy, they clean your blood. They also make hormones that keep your bones strong and your blood healthy. When your kidneys fail, you need treatment to replace the work your kidneys used to do. Unless you have a kidney transplant, you will need a treatment called dialysis.

There are two main types of dialysis: hemodialysis and peritoneal dialysis. Both types filter your blood to rid your body of harmful wastes, extra salt and water. Hemodialysis does that with a machine. Peritoneal dialysis uses the lining of your abdomen, called the peritoneal membrane, to filter your blood. Each type has both risks and benefits. They also require that you follow a special diet. Your doctor can help you decide the best type of dialysis for you.
Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo. [More]
DaVita HealthCare Partners recognizes May as Employee Health Month

DaVita HealthCare Partners recognizes May as Employee Health Month

DaVita HealthCare Partners Inc., one of the nation's largest and most innovative health care communities, recognizes the month of May as Employee Health Month. The health of teammates is vital in helping to ensure they can provide the best quality of care for DaVita HealthCare Partners' patients. [More]
Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

Phosphate Therapeutics Limited, a development-stage specialty pharmaceuticals company, today announces positive results from the PEACH pivotal study of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD). [More]
DaVita Way of Giving program receives Communitas Award

DaVita Way of Giving program receives Communitas Award

DaVita HealthCare Partners Inc., one of the nation's largest and most innovative health care communities, today announced that the company received a Communitas Award for its DaVita Way of Giving program. [More]
Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS). [More]
Bayshore HealthCare achieves BPSO designation

Bayshore HealthCare achieves BPSO designation

Bayshore HealthCare Ltd. is pleased to announce that it has achieved the designation of Best Practice Spotlight Organization presented by the Registered Nurses' Association of Ontario. [More]
NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Pharmalink AB, a specialty pharma company, today announces that the NEFIGAN Trial of Nefecon for the treatment of primary IgA nephropathy has fully met its primary efficacy endpoint at a planned interim analysis and been stopped early with respect to statistical analysis of the endpoint. [More]
New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that clinical data for simeprevir, its NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver taking place in Vienna from April 22-26. [More]
New oral drug shows promise in patients with chronic kidney disease

New oral drug shows promise in patients with chronic kidney disease

Patients with chronic kidney disease may be treated with a class of medications called Renin Angiotensin Aldosterone System inhibitors (RAASI's). Although these drugs protect the heart and kidney, a significant percentage of patients develop a dangerous side effect -- high potassium levels in the blood (hyperkalemia). [More]
DaVita Kidney Care celebrates its dietitians and social workers

DaVita Kidney Care celebrates its dietitians and social workers

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, is celebrating its more than 3,600 dietitians and social workers during March for their distinctive and important roles in patient care. [More]
Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. [More]
TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

TVA Medical, Inc., today announced promising results from a clinical study evaluating a novel hemodialysis access technique that has the potential to revolutionize vascular access for patients with chronic kidney disease without the use of traditional open surgery. [More]
DCR representatives to present health-related quality posters at NKF's 2015 Spring Clinical Meeting

DCR representatives to present health-related quality posters at NKF's 2015 Spring Clinical Meeting

DaVita Clinical Research, a specialty contract research organization with services spanning the full spectrum of drug and device development and subsidiary of DaVita HealthCare Partners Inc., today announced that company representatives will present health-related quality posters at National Kidney Foundation's 2015 Spring Clinical Meeting, which takes place March 25-29, 2015 in Dallas. [More]
Testing APOL1 gene variants in deceased kidney donors may improve transplant outcomes

Testing APOL1 gene variants in deceased kidney donors may improve transplant outcomes

Kidney transplantation outcomes from deceased African-American donors may improve through rapid testing for apolipoprotein L1 gene (APOL1) renal risk variants at the time of organ recovery, according to a new study led by researchers at Wake Forest Baptist Medical Center. [More]
Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid. [More]
DaVita HealthCare Partners named Metro Denver's healthiest extra-large employer

DaVita HealthCare Partners named Metro Denver's healthiest extra-large employer

DaVita HealthCare Partners Inc., one of the nation's largest and most innovative health care communities, has been recognized by the Denver Business Journal as Metro Denver's healthiest extra-large employer. This is the fourth consecutive year the company has topped the list because of its commitment to teammate health and wellness. [More]
Study provide new insights into why childhood CKD may worsen to kidney failure

Study provide new insights into why childhood CKD may worsen to kidney failure

Study results published today in the National Kidney Foundation's American Journal of Kidney Diseases provide new insights into why a child's chronic kidney disease (CKD) may worsen to kidney failure. [More]
Astute Medical hails launch of collaborative global initiative to prevent deaths from AKI by 2025

Astute Medical hails launch of collaborative global initiative to prevent deaths from AKI by 2025

Astute Medical, Inc. today hailed the launch of a collaborative global initiative calling for the elimination of preventable deaths from acute kidney injury (AKI) by 2025. The Company cited the publication of a new Commission from The Lancet and the International Society of Nephrology, along with the release of results from the 0by25 AKI "Global Snapshot" study, as key steps forward in the effort to reduce the global burden of AKI. [More]
Lancet study: Most people lack access to life-saving treatments for kidney failure

Lancet study: Most people lack access to life-saving treatments for kidney failure

New estimates published in The Lancet indicate that at best only half of people worldwide needing kidney dialysis or transplantation to treat kidney failure in 2010 received it. This suggests that at least 2.3 million people may have died prematurely from kidney failure because they could not access this life-saving treatment. [More]
Medical experts aim to offer lifesaving treatments to eliminate preventable deaths from AKI by 2025

Medical experts aim to offer lifesaving treatments to eliminate preventable deaths from AKI by 2025

Preventable deaths caused by acute kidney injury (AKI) could be nearly eliminated in just 10 years, according to leading medical experts. This often forgotten condition - which affects around 13 million people every year and contributes to 1.7 million deaths annually - is preventable and can be treated for as little as $US150 per patient. [More]
Advertisement